3 Indian Companies Capturing the Global Medical Consumables Opportunity

Synopsis:- Global hospitals and laboratories are leaning more heavily on Indian manufacturers for IV cannulas, labware and home health devices, and three listed companies sit at different stages of that opportunity. One is funding a multi-year capacity build, another is digesting the cost of past expansion, and the third is rebuilding earnings after a volatile year, even as each holds a distinct foothold in regulated export markets.

Hospitals and diagnostic labs in the United States and Europe have spent the past several years diversifying their supplier base away from China, and Indian manufacturers with patent portfolios, FDA clearances or CE certifications have been among the beneficiaries. The opportunity is real, but it does not show up identically in each company’s numbers.

Poly Medicure

Poly Medicure ranks among the top three global manufacturers of IV cannulas and exports across 12 clinical specialties to hospitals in more than 125 countries, backed by over 370 international patents that clear CE and FDA approvals most domestic peers cannot match. The company is mid-way through a large capacity expansion, with fixed assets nearly doubling over the past year, and management has signalled further capex ahead as it builds out manufacturing lines for higher-value consumables. That investment phase, not the current quarter’s profit line, is what will determine whether the next leg of export growth gets captured.

With a market capitalisation of Rs. 16,724.32 crore, the shares of Poly Medicure closed on Thursday at Rs. 1,650 per share, down 0.05 percent from its previous close of 1,650.90. It is trading at a P/E of 53.11.

For FY26, Poly Medicure reported consolidated revenue of Rs. 1,875 crore against Rs. 1,669 crore in FY25, a 12.3 percent increase. Net profit came in at Rs. 321 crore versus Rs. 339 crore in FY25, with the decline explained almost entirely by higher depreciation fixed assets on the balance sheet expanded from Rs. 1,084 crore to Rs. 1,702 crore in FY26, reflecting significant new capacity investment. Free cash flow turned negative at Rs. 59 crore as a result. Over five years, the company has compounded revenue at 19 percent and net profit at 19 percent annually, a track record that gives context to the near-term earnings pressure from its capex cycle.

Tarsons Products

Tarsons Products designs and manufactures labware including centrifuge tubes, cryogenic vials and cell-culture consumables used across diagnostic and pharmaceutical research labs in more than 100 countries, distributed directly and through its Singapore subsidiary. The company’s near-term story is less about demand and more about digesting the cost of its own expansion: operating margins have compressed from above 50 percent five years ago to under 30 percent now, as depreciation and interest costs from new manufacturing capacity have outpaced revenue growth. Management’s commentary points to recovering utilisation at newer facilities as the lever that could restore margins, though that recovery has yet to show up in reported numbers.

With a market capitalization of Rs. 1,385.49 crore, the shares of Tarsons Products closed on Thursday at Rs. 260.40 per share, up 0.83 percent from its previous closing price of Rs. 258.26 apiece. It is trading at a P/E of 95.94.

For FY26, Tarsons reported consolidated revenue of Rs. 423 crore against Rs. 392 crore in FY25, but net profit fell 52 percent to Rs. 14 crore from Rs. 30 crore as depreciation nearly doubled and borrowings rose to Rs. 393 crore. Free cash flow stayed negative at Rs. 7 crore, and the cash conversion cycle remains stretched at over 360 days. At a trailing P/E above 95, the stock is pricing in a margin recovery that the balance sheet has not yet delivered, and promoter holding of 47.3 percent has stayed flat through the downturn even as FII ownership has fallen sharply over the past year.

Nureca

Nureca operates a digital-first consumer healthcare model under the Dr Trust and Dr Physio brands, selling home diagnostics, wellness devices and physiotherapy equipment through online channels that account for over 90 percent of revenue, an asset-light structure unusual among the manufacturers in this group. The company swung between profit and loss through FY26, and a fourth-quarter net loss of Rs. 6.09 crore erased much of the gains from the first three quarters even as full-year revenue grew 34 percent.

Management has attributed the volatility to raw material cost spikes and sourcing changes, and the company remains debt-free with promoter holding raised to over 68 percent following a buyback completed in December.

With a market capitalisation of approximately Rs. 229.86 crore, the shares of Nureca closed on Thursday at Rs. 240.90 per share, up 0.96 percent from its previous closing price of Rs. 238.60 apiece. The stock’s trailing P/E has been pushed above 100 by the thin full-year profit base, a figure that reflects the FY26 earnings swing rather than any conventional read on valuation.

For FY26, Nureca reported consolidated revenue of Rs. 147 crore against Rs. 110 crore in FY25, a 34 percent increase, while net profit rose to Rs. 2.08 crore from Rs. 0.85 crore, though that full-year number masks a loss-making fourth quarter. Working capital days have compressed to 148 from 434 a year earlier, a flag worth watching given that the company’s asset-light positioning is supposed to keep capital intensity low rather than rising it.

Taken together, the three companies illustrate how unevenly an export tailwind can land on a balance sheet. Poly Medicure’s capex cycle and Tarsons’ margin compression both stem from scaling manufacturing ahead of demand, while Nureca’s swings come from a leaner, online-first model that trades capital intensity for earnings volatility. The underlying export opportunity in medical consumables looks intact across all three; whether each company’s current numbers reflect that opportunity or simply the cost of chasing it is the question worth tracking through the next two or three quarters.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post 3 Indian Companies Capturing the Global Medical Consumables Opportunity appeared first on Trade Brains.